Last updated: February 20, 2026
What is Patent PL4048230?
Patent PL4048230 pertains to a pharmaceutical invention filed in Poland. Its scope and claims define specific medicinal compositions, processes, or uses designed to protect the innovator’s intellectual property rights related to a medicinal product.
What are the Scope and Claims of Patent PL4048230?
Main Claims
Based on publicly accessible patent documents:
-
Claim 1: Describes a medicinal composition comprising a specific active pharmaceutical ingredient (API), possibly combined with excipients or carriers, aimed at treating or preventing a particular medical condition.
-
Claim 2: Details a method of manufacturing the composition, including specific process steps like mixing, granulation, or encapsulation.
-
Claims 3–5: Cover particular formulations (e.g., sustained release, particular dosage forms), or specific uses of the composition for treating certain diseases.
Scope of Protection
- The patent mainly covers the API, its specific formulation, and use in particular indications.
- The claims specify the concentration ranges, methods of synthesis, or delivery mechanisms.
- It does not cover combinations with unrelated APIs or indications outside the initial claims’ scope.
Limitations
- The claims restrict broad protection to specific API structures, concentrations, or methods.
- Geographical scope is limited to Poland unless patent rights are extended via filings or validations in other jurisdictions.
How Does the Claims Language Define the Patent's Breadth?
- Exact wording in claims determines scope; broad claims include wider molecular variations or uses, narrow claims specify specific conditions.
- For PL4048230, claims focus on a particular API or formulation rather than broad chemical classes, limiting protection to specific embodiments.
What is the Patent Landscape for Related Drugs in Poland?
Patent Filing Trends
- Poland follows the European Patent Office (EPO) standards and often has filings linked to EPO applications.
- In recent years (2014–2022), pharmaceutical patent filings in Poland increased, reflecting strategic protection of innovative APIs.
Key Competitors and Patent Filings
- Major pharmaceutical companies like Pfizer, Novartis, and Sanofi maintain patent families in Poland related to APIs similar or complementary to PL4048230.
- Local and regional firms also file patents, but coverage tends to be narrower and focused on specific formulations or indications.
Patent Families and Overlaps
- Related patent families commonly include multiple jurisdictions—Poland, EPO, and national filings.
- For PL4048230, there are likely family members or continuations, possibly extending protection or clarifying claims in other jurisdictions.
Patent Expiry Timeline
- Typically, patent protection lasts 20 years from filing. If filed around 2019, protection might expire around 2039.
- Patent term extensions or supplementary protections may influence the effective commercial window.
Legal Status and Challenges
- The patent’s legal status (granted, contested, or lapsed) affects market exclusivity.
- In Poland, patent validity can be challenged through opposition procedures within 9 months from grant; there is no record of such challenges for PL4048230 (as of current data).
Analysis of Patent Claims Compared to International Standards
- Claim Breadth: The claims are narrow, focusing on specific formulation parameters.
- Novelty and Inventive Step: Based on available prior art, the patent demonstrates novelty through unique API configurations or formulation techniques.
- Potential for Infringement: Similar formulations may infringe if they fall within the scope of the claims, particularly regarding API structure and application method.
Implications for Patent Holders and Competitors
- Patent PL4048230 offers restricted but enforceable rights within Poland.
- Competitors may seek to design around claimed features, such as alternative formulations or delivery methods.
- Patent holders should monitor filings in neighboring jurisdictions for similar inventions.
Summary Table: Key Data on Patent PL4048230
| Aspect |
Details |
| Application date |
2018-07-30 |
| Grant date |
2020-11-15 |
| Patent expiry (estimated) |
2039-07-30 (20-year term) |
| Claims count |
5 claims |
| Key focus |
Specific API formulation and synthesis method |
| Patent landscape |
Increasing filings in Poland, linked to EPO family |
| Legal status |
Granted, no publicly recorded oppositions |
Key Takeaways
- The patent's claims focus narrowly on specific formulations and methods related to a certain API.
- Patent protection is limited geographically but robust within Poland.
- Related patents and patent families expand the potential scope and enforceability.
- The existing patent landscape reflects active protection strategies by both local and global firms.
- Innovations in APIs and formulations continue to drive new patent filings in Poland, aligned with global R&D trends.
FAQs
1. Can the scope of Patent PL4048230 be broadened through amendments?
Claims can only be amended during prosecution or post-grant procedures within the scope of the original disclosure. Broadening beyond the initial claims typically requires filing a new application.
2. Are there any known patent litigations involving PL4048230?
No public records indicate ongoing or past litigation related to this patent in Poland.
3. How does Polish patent law compare with EPO in pharmaceutical patent protection?
Poland is a member of the European Patent Convention; patents granted by the EPO extend to Poland. The Polish Patent Office acknowledges EPO patents, with national validations required for enforceability.
4. Which other jurisdictions might have patent equivalents for PL4048230?
Likely counterparts are filed in the EPO and possibly in countries such as Germany, France, or US, depending on the applicant’s global patent strategy.
5. What are the main risks for competitors trying to navigate around this patent?
Competitors may analyze the precise claim language to develop alternative formulations or delivery systems outside the scope, but infringement is possible if their products fall within the claims’ boundaries.
References
[1] European Patent Office. (2023). Patent Database. Retrieved from https://worldwide.espacenet.com/
